Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMESLE-2
2024-512716-21-00Phase 3Withdrawn
- Sponsor
- RemeGen
- Start
- Jan 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Telitacicept + standard of care with Placebo + standard of care (2 arms). Planned start Jan 2025; status: withdrawn.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-512716-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512716-21-00.